O. S. Hoekstra

2.5k total citations · 1 hit paper
35 papers, 1.9k citations indexed

About

O. S. Hoekstra is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, O. S. Hoekstra has authored 35 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 14 papers in Radiology, Nuclear Medicine and Imaging and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in O. S. Hoekstra's work include Radiomics and Machine Learning in Medical Imaging (7 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Medical Imaging Techniques and Applications (6 papers). O. S. Hoekstra is often cited by papers focused on Radiomics and Machine Learning in Medical Imaging (7 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Medical Imaging Techniques and Applications (6 papers). O. S. Hoekstra collaborates with scholars based in Netherlands, United States and United Kingdom. O. S. Hoekstra's co-authors include Jan Pruim, Adriaan A. Lammertsma, Helen Young, Karl Herholz, U. Cremerius, Pat Price, R. Baum, S. Meijer, Henk van Veen and M.A. Paul and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

O. S. Hoekstra

34 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations

1999 1.4k citations Helen Young, R. Baum et al. European Journal of Cancer profile →

Peers

Countries citing papers authored by O. S. Hoekstra

Since Specialization

Citations

This map shows the geographic impact of O. S. Hoekstra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O. S. Hoekstra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O. S. Hoekstra more than expected).

Fields of papers citing papers by O. S. Hoekstra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by O. S. Hoekstra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O. S. Hoekstra. The network helps show where O. S. Hoekstra may publish in the future.

Co-authorship network of co-authors of O. S. Hoekstra

This figure shows the co-authorship network connecting the top 25 collaborators of O. S. Hoekstra. A scholar is included among the top collaborators of O. S. Hoekstra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with O. S. Hoekstra. O. S. Hoekstra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P1.04-12 Tumor Uptake and Biodistribution of 89Zr-Labeled Pembrolizumab in Patients with Metastatic Non-Small-Cell Lung Cancer 2019 ·Journal of Thoracic Oncology ·Anna-Larissa N. Niemeijer, Daniela E. Oprea‐Lager, (unknown), Ronald Boellaard, O. S. Hoekstra, (unknown), Idris Bahce, Daniëlle J. Vugts, Guus A.M.S. van Dongen, Erik Thunnissen, Egbert F. Smit, J. De Langen	2
2	Abstract PD4-09: Non-invasive estrogen receptor assessment by [18F]-fluorestradiol(FES)-PET or circulating tumor cells predicts receptor status in patients with metastatic breast cancer 2019 ·Cancer Research ·(unknown), Lindsay Angus, Bert van der Vegt, (unknown), Jaco Kraan, (unknown), Andor W.J.M. Glaudemans, Adrienne H. Brouwers, O. S. Hoekstra, Wim J.G. Oyen, Jasper Emmering, (unknown), (unknown), Eline Boon, (unknown), (unknown), Stefan Sleijfer, Elisabeth G.E. de Vries, (unknown)	1
3	Whole body PD-1 and PD-L1 PET in pts with NSCLC 2017 ·Annals of Oncology ·(unknown), Egbert F. Smit, Idris Bahce, O. S. Hoekstra, (unknown), Guus AMS van Dongen, Albert D. Windhorst, N. Harry Hendrikse, Alex J. Poot, Daniëlle J. Vugts, David Leung, Wendy Hayes, R. Adam Smith, L. Wilson, Erik Thunnissen, J. De Langen	3
4	ImmunoPET imaging to assess target engagement: Experience from Zr-89-anti-HER3 mAb (GSK2849330) in patients with solid tumors 2017 ·Pure Amsterdam UMC ·Adam McGeoch, (unknown), Mats Bergström, (unknown), (unknown), (unknown), O. S. Hoekstra, Daniëlle J. Vugts, (unknown), Immanuel Freedman, (unknown), Christopher Matheny, Guus A.M.S. van Dongen, (unknown)	5
5	89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation in a dose-dependent manner and role of IL-2 receptor-binding 2016 ·Annals of Oncology ·(unknown), Emilie M.J. van Brummelen, Tapan K. Nayak, Marc C. Huisman, (unknown), Emma R. Mulder, O. S. Hoekstra, Marcel P. M. Stokkel, Guus AMS van Dongen, Henk M.W. Verheul, (unknown), (unknown), Ernesto Guarin, Stefan Evers, Jose Saro, Jan H.M. Schellens	3
6	Survival and Recurrence in Clinical Stage III Melanoma Patients with Whole Body FDG-PET and CT Added to the Diagnostic Work-up 2013 ·Annals of Surgical Oncology ·(unknown), Esther Bastiaannet, O. S. Hoekstra, Han J. Bonenkamp, Ron Koelemij, Harald Hoekstra	1
7	A phase II study of erlotinib (E) and bevacizumab (B) in chemo naive patients (pts) with locally advanced or metastatic non small cell lung cancer (NSCLC): Predictive value of molecular imaging 2008 ·Journal of Clinical Oncology ·(unknown), Adrianus J. de Langen, Harry J.M. Groen, J. Tim Marcus, Peter Kappert, Walter H. Backes, Boudewijn Brans, O. S. Hoekstra, Anne‐Marie C. Dingemans, Egbert F. Smit	1
8	Feasibility of a randomized trial on adjuvant radio‐iodine therapy in differentiated thyroid cancer 2003 ·Clinical Endocrinology ·(unknown), O. S. Hoekstra, D.J. Kuik, Paul Lips, (unknown), Patrick Rodrigus, (unknown), J. G. Ribot, J. L. P. Kuijpens, J.W.W. Coebergh, G. J. J. Teule	11
9	[Surgery and referral for subsequent 131I therapy for patients with differentiated thyroid carcinoma in the south-east of the Netherlands, 1983-1996, compared to the consensus guidelines from 1987]. 2002 ·PubMed ·J. L. P. Kuijpens, O. S. Hoekstra, J. F. Hamming, Harm R. Haak, J. G. Ribot, J.W.W. Coebergh	3
10	Failure patterns of combined modality treatment in lung cancer: the impact of staging. 2002 ·PubMed ·C. Hoekstra, Herman Rijna, Egbert F. Smit, Johan C. van Mourik, Pieter E. Postmus, Adriaan A. Lammertsma, O. S. Hoekstra	1
11	Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer 2001 ·European Journal of Cancer ·Patrick Flamen, O. S. Hoekstra, (unknown), Eric Van Cutsem, Alex Maes, Sigrid Stroobants, Marc Peeters, Freddy Penninckx, Ludo Filez, R. P. Bleichrodt, Luc Mortelmans	103
12	A phase II study of paclitaxel in chemonaïve patients with recurrent high-grade glioma 2000 ·Annals of Oncology ·Tjeerd J. Postma, J.J. Heimans, (unknown), C.J. van Groeningen, Ludo F.M. Beenen, O. S. Hoekstra, (unknown), Bernard A. Zonnenberg, Martin Klein, Jan B. Vermorken	37
13	Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations breakdown → 1999 ·European Journal of Cancer ·Helen Young, R. Baum, U. Cremerius, Karl Herholz, O. S. Hoekstra, Adriaan A. Lammertsma, Jan Pruim, Pat Price	1364
14	Thoracic Actinomycosis Imaging With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography 1999 ·Clinical Nuclear Medicine ·C. Hoekstra, O. S. Hoekstra, (unknown), PE Postmus, Egbert F. Smit	14
15	Transport and retention of colloidal tracers in regional lymphoscintigraphy in melanoma: influence on lymphatic mapping and sentinel node biopsy 1998 ·Melanoma Research ·Rik Pijpers, Paul J. Borgstein, S. Meijer, David N. Krag, O. S. Hoekstra, Henri N. Greuter, G. J. J. Teule	20
16	Clinical effectiveness of 99mTc-diphosphonate scintigraphy of revascularized iliac crest flaps 1996 ·International Journal of Oral and Maxillofacial Surgery ·Ludi E. Smeele, O. S. Hoekstra, Henri A. H. Winters, C. René Leemans	21
17	Technetium-99m-sestamibi/thallium-201 mismatch of thyroid and parathyroid adenoma in chronic renal failure. 1995 ·PubMed ·Rik Pijpers, B.J. Potter van Loon, Jan C. Roos, O. S. Hoekstra	5
18	Tumour-induced hypoglycaemia: A case report 1994 ·Annals of Oncology ·Klaas Hoekman, (unknown), Ton Gloudemans, O. S. Hoekstra, J. A. Maassen, J. B. Vermorken, John Wagstaff, Herbert M. Pinedo	6
19	Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy 1994 ·British journal of surgery ·Henk van Veen, O. S. Hoekstra, M.A. Paul, Miguel A. Cuesta, S. Meijer	166
20	Therapeutic potential of intravenous 67‐gallium in non‐Hodgkin's lymphoma 1993 ·European Journal Of Haematology ·Peter C. Huijgens, Andries R. Jonkhoff, O. S. Hoekstra, G.J. Ossenkoppele, G. J. J. Teule	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact